Effectiveness and safety analysis of roxadustat in the treatment of peritoneal dialysis patients with renal anemia
Objective To explore the effectiveness and safety of roxadustat in the treatment of peritoneal dialysis patients with renal anemia.Methods 50 cases of peritoneal dialysis patients with renal anemia were randomly divided into a control group and a study group,with 25 cases in each group.The control group was treated with recombinant human erythropoietin injection,and the study group was treated with roxadustat.The therapeutic effect,anemia-related indexes[hemoglobin(Hb),red blood cell count(RBC),hematocrit(Hct)]and incidence of adverse reactions were compared between the two groups.Results The total clinical effective rate of 100.0%in the study group was higher than 76.0%in the control group(P<0.05).Before treatment,there were no significant differences in Hb,RBC and Hct levels between the two groups(P>0.05).After 4 and 12 weeks of treatment,Hb,RBC and Hct levels in the study group were(92.3±5.6)g/L,(3.8±0.3)×1012/L,(32.8±2.2)%and(100.2±8.9)g/L,(4.5±1.0)×1012/L,(42.5±6.3)%,which were higher than(87.3±4.2)g/L,(3.2±1.0)×1012/L,(27.9±3.0)%and(90.5±3.3)g/L,(3.9±0.8)×1012/L,(33.0±2.3)%in the control group(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The effect of applying roxadustat treatment to peritoneal dialysis patients with renal anemia is remarkable,which can effectively improve the level of anemia-related indicators,and there is no significant increase in adverse reactions,which can ensure the clinical safety of patients.
RoxadustatPeritoneal dialysis renal anemiaRecombinant human erythropoietin injectionAnemia indexSafetyEffectiveness
万方数据
维普
